Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) Starts Presentation at 29th Annual Roth Conference
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical-stage biopharmaceutical company that discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Pieris primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment…